The rationale for the use of immune checkpoint inhibitors as a promising alternative to conventional cytotoxic agents in patients with gynecological cancers was, among others, based on the immunohistological studies of the expression levels of PD-1 and PD-L1. The gene discussed is PDCD1; the disease is female reproductive organ cancer.